Therini Bio

The company is backed by a syndicate of investors in life sciences and neurodegenerative diseases.

Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.

Therini Bio is developing therapeutics based on insights into fibrin’s role in chronic innate immune activation across human diseases. Its address is 2108 N St. Suite 4963, Sacramento, CA 95816.

Therini Bio initiates a Phase 1b trial of its experimental anti-inflammatory drug **THN391**, targeting **diabetic macular edema**. The company also progresses **THN622**, a fibrin/VEGF bispecific antibody, as a potential new treatment for retinal neurodegeneration. Both programs aim to address unmet needs in ophthalmology.

May 2026Therini BioNews article

Therini Bio begins dosing the first patient in a Phase 1b trial of **THN391**, a therapy targeting chronic neuroinflammation linked to Alzheimer’s disease. The study evaluates safety, pharmacokinetics (PK), and early efficacy signals. Researchers aim to assess whether the treatment can disrupt disease progression by addressing neuroinflammatory pathways.

Jul 2025Therini BioNews article

Therini Bio secures an additional **$39 million in Series A funding**, totaling **$75 million**, to advance clinical trials for neurodegenerative diseases. The company plans to initiate **Phase 1b studies** for its lead candidate, **THN391**, targeting Alzheimer’s disease (AD) and dementia with mild cognitive impairment (DME). Investors include top-tier backers supporting the pipeline’s development.

May 2025GlobeNewswireNews article

Therini Bio reports positive Phase 1a trial results for its experimental drug **THN391**, a novel candidate targeting neurodegenerative diseases. Early safety and efficacy data suggest potential therapeutic benefits in treating conditions like Alzheimer’s or Parkinson’s. The company’s approach focuses on a mechanism distinct from existing treatments, marking progress in addressing unmet medical needs. Further trials are expected to validate these findings.

Apr 2025GlobeNewswireNews article